Ansprechpartner

Abteilungsleitung:
Prof. Dr. Dirk Jäger
E-Mail

Publikationen

  1. Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, Haldipur P, Kawauchi D, Risch T, Warnatz HJ, Worst BC, Ju B, Orr BA, Zeid R, Polaski DR, Segura-Wang M, Waszak SM, Jones DT, Kool M, Hovestadt V, Buchhalter I, Sieber L, Johann P, Chavez L, Gröschel S, Ryzhova M, Korshunov A, Chen W, Chizhikov VV, Millen KJ, Amstislavskiy V, Lehrach H, Yaspo ML, Eils R, Lichter P, Korbel JO, Pfister SM, Bradner JE, Northcott PA. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature. 2016;530(7588):57-62.
  2. Zschäbitz S, Lasitschka F, Jäger D, Grüllich C. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors. Annals of Oncology. 2016;27(7):1356-60.
  3. Haag G, Stocker G. Adenokarzinom des Ösophagus und des Magens - palliative Konzepte. Trillium-Krebsmedizin. 2016;25(2).
  4. Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016;101(7):872-8.
  5. Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia. 2016:E1-E12.
  6. Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab M, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J. Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. Eur Radiol. 2016;26(11):3939-48.
  7. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Grobner S, Brabetz S, Chavez L, Bens S, Gröschel S, Kratochwil F, Wittmann A, Sieber L, Geörg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schuller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Frühwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M. Atypical Teratoid Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. 2016;29(3):379-93.
  8. Avellino R, Havermans M, Erpelinck C, Sanders MA, Hoogenboezem R, van de Werken HJ, Rombouts E, van Lom K, van Strien PM, Gebhard C, Rehli M, Pimanda J, Beck D, Erkeland S, Kuiken T, de Looper H, Gröschel S, Touw I, Bindels E, Delwel R. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation. Blood. 2016;127(24):2991-3003.
  9. Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. American journal of hematology. 2016;91(11):E473-E7.
  10. Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jaeger D, Heikenwalder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Koehler BC. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7(8):E1-E10.
  11. Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain, behavior, and immunity. 2016;52:98-105.
  12. Jensen AD, Poulakis M, Vanoni V, Uhl M, Chaudhri N, Federspil PA, Freier K, Krauss J, Debus J. Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? Radiation oncology. 2016;11(1):90E1-E9.
  13. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Investigators E. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. The Lancet Oncology. 2016;17(1):27-38.
  14. Halama N. CCR5 inhibition in colorectal cancer patients. Transl Cancer Res. 2016;5:S366-S7.
  15. Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J. Chetomin, targeting HIF-1 alpha/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer. 2016;114(5):519-23.
  16. Schmoch T, Gal Z, Mock A, Mossemann J, Lahrmann B, Grabe N, Schmezer P, Lasitschka F, Beckhove P, Unterberg A, Herold-Mende C. Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. Anticancer Res. 2016;36(4):1489-96.
  17. Rios-Tamayo R, Lupianez CB, Campa D, Hielscher T, Weinhold N, Martinez-Lopez J, Jerez A, Landi S, Jamroziak K, Dumontet C, Watek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, Garcia-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Forsti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016;7(37):59029-48.
  18. Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):E116-E9.
  19. Bouman A, Knegt L, Gröschel S, Erpelinck C, Sanders M, Delwel R, Kuijpers T, Cobben JM. Congenital thrombocytopenia in a neonate with an interstitial microdeletion of 3q26.2q26.31. Am J Med Genet A. 2016;170(2):504-9.
  20. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016;30(4):937-46.
  21. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2016;375(14):1319-31.
  22. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Thery C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vely F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):E1-E13.
  23. Kuehl R, Schmidt ME, Dreger P, Steindorf K, Bohus M, Wiskemann J. Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016;24(10):4327-37.
  24. Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W. Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011. Oncol Lett. 2016;12(6):5043-51.
  25. Kittas A, Delobelle A, Schmitt S, Breuhahn K, Guziolowski C, Grabe N. Directed random walks and constraint programming reveal active pathways in hepatocyte growth factor signaling. The FEBS journal. 2016;283(2):350-60.
  26. Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS. Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol Oncol. 2016;34(4):200-7.
  27. Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C. Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer. Z Gastroenterol. 2016;54(5):426-30.
  28. Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, Roth W, Grüllich C, Huesing J, Duensing S, Pahernik S. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbeck's archives of surgery. 2016:E1-E8.
  29. Wiskemann J, Schmidt ME, Klassen O, Debus J, Ulrich CM, Potthoff K, Steindorf K. Effects of 12-week resistance training during radiotherapy in breast cancer patients. Scandinavian journal of medicine & science in sports. 2016.
  30. Wanjek M, Senner V, F. S-R, Halle M. Effects of different weight loss intervention programmes in health clubs - an observational multicenter study. European Journal of Sport Science. 2016;16(7):859-67.
  31. Apostolidis L, Bergmann F, Jäger D, Winkler EC. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med. 2016;5(9):2261-7.
  32. Mehlis K, Winkler EC. Ethical analysis of life-prolonging treatment. For protection of self-determination and protection against overtreatment. Onkologe. 2016;22(11):844-51.
  33. Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, Brenner H. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Scientific reports. 2016;6:25467E1-E10.
  34. Wiskemann J, Scharhag-Rosenberger F. The evolving role of exercise in cancer patients: recent developments, recommendations and future directions 2016. Future oncology. 2016;12(13):E1-E4.
  35. Wiskemann J, Schommer K, Jaeger D, Scharhag-Rosenberger F. Exercise and cancer: return to work as a firefighter with ostomy after rectal carcinoma - a case report. Medicine. 2016;95(29):E1-E6.
  36. Winkler EC, Heussner P. Farsighted Planning of Treatment and Therapy Limitation Considerations from medico-ethical and psycho-oncological View. Dtsch Med Wochenschr. 2016;141(6):394-8.
  37. Ziegler C, Finke J, Grüllich C. Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95. Leukemia Lymphoma. 2016;57(1):177-82.
  38. Winkler EC, Wiemann S. Findings made in gene panel to whole genome sequencing: data, knowledge, ethics - and consequences? Expert Rev Mol Diagn. 2016;16(12):1259-70.
  39. Lisenko K, Schönland SO, Jauch A, Andrulis M, Rocken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Med. 2016;5(7):1464-72.
  40. Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2016;30(4):873-82.
  41. Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016. 1-16
  42. Friedel M, Andre S, Goldschmidt H, Gabius HJ, Schwartz-Albiez R. Galectin-8 enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse prognostic factor. Glycobiology. 2016;26(10):1048-58.
  43. Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P, Grp IMW. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016;30(5):1071-8.
  44. Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Försti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia. 2016;30(4):883-8.
  45. Campo C, Da Silva Filho MI, Weinhold N, Goldschmidt H, Hemminki K, Merz M, Försti A. Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci. Neurochemical research. 2016.
  46. Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Joud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nothen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.
  47. Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Noethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016;7:10290E1-E7.
  48. Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jäger D, Haberkorn U, Arndt MA, Krauss J. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. European journal of nuclear medicine and molecular imaging. 2016;43(3):489-98.
  49. Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Hoss A, Haberer T, Jakel O, Munter MW, Schulz-Ertner D, Huber PE, Debus J. High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016;118(2):272-80.
  50. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Konigsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet Oncology. 2016;17(12):1697-708.
  51. Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Hofer T, Trumpp A, Halama N, Hassel JC, Strobel O, Buchler M, Sahin U, Offringa R. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):E1-E13.
  52. Kosaloglu Z, Zörnig I, Halama N, Kaiser I, Buchhalter I, Grabe N, Eils R, Schlesner M, Califano A, Jäger D. Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. Oncoimmunology. 2016;5(11):E1-E10.
  53. Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot and feasibility studies. 2016;2:18E1-E0.
  54. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Maqueda MA, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer. 2016;59:160-70.
  55. Jäger D, Halama N, Zörnig I, Klug P, Krauss J, Haag GM. Immunotherapy of Colorectal Cancer. Oncol Res Treat. 2016;39(6):346-50.
  56. Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. J Neurooncol. 2016;130(1):221-8.
  57. Kosaloglu Z, Bitzer J, Halama N, Huang ZQ, Zapatka M, Schneeweiss A, Jäger D, Zörnig I. In silico SNP analysis of the breast cancer antigen NY-BR-1. BMC Cancer. 2016;16:901E1-E12.
  58. Hemminki K, Försti A, Tuuminen R, Hemminki O, Goldschmidt H, Sundquist K, Sundquist J, Li X. The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications. Scientific reports. 2016;6:28500E1-E7.
  59. Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S. Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. Br J Haematol. 2016;174(1):127-35.
  60. Eckrich F, Baudendistel I, Ose D, Winkler EC. Influence of electronic medical records (EMR) on the physician-patient relationship: a systematic review of the medical and ethical implications. Ethik Med. 2016;28(4):295-310.
  61. Heining C, Richter D, Gröschel S, Glimm H, Fröhling S. Integration der Genomsequenzierung in die klinische Hämato-Onkologie – Eine Möglichkeit für „personalisierte“ Therapien. TumorDiagn u Ther. 2016;37(06):332-6.
  62. Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Georg C, Richter D, Pfarr N, Pfutze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harbor molecular case studies. 2016;2(6):E1-E13.
  63. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology. 2016;17(8):E328-E46.
  64. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of clinical oncology. 2016;34(13):1544-57.
  65. Wiskemann J, Dehler D. Körperliches Aktivitätsverhalten postoperativer Darmkrebspatienten und die Anwendbarkeit sporttherapeutischer Maßnahmen in Fallbeispielen. B & G. 2016;32(2):55-9.
  66. Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M. Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology. 2016;5(5):e1139662.
  67. Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. International journal of cancer. 2016;139(2):424-32.
  68. Du Y, Grüllich C, Hadaschik B, Hatiboglu G, Hohenfellner M, Pahernik S. Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. Clinical genitourinary cancer. 2016;14(4):e379-85.
  69. Grüllich C, Vallet S, Hecht C, Duensing S, Hadaschik B, Jäger D, Hohenfellner M, Pahernik S. Local salvage therapy for late (>/=2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. Urologic oncology. 2016;34(5):238 E9-E17.
  70. Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, Strobel O, Jäger D, Ulrich A, Büchler MW. Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg. 2016;264(3):457-63.
  71. Echterdiek F, Janikovits J, Staffa L, Muller M, Lahrmann B, Frühschütz M, Hartog B, Nelius N, Benner A, Tariverdian M, von Knebel Doeberitz M, Grabe N, Kloor M. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology. 2016;5(2):E1-E8.
  72. Lehners N, Hayden PJ, Goldschmidt H, Raab MS. Management of high-risk Myeloma: an evidence-based review of treatment strategies. Expert Rev Hematol. 2016;9(8):753-65.
  73. Bashari MH, Fan FJ, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 2016;18:26 E1-E15.
  74. Merz M, Hillengass J, Goldschmidt H. Meeting report of the 5th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma. Journal of cancer research and clinical oncology. 2016;142(1):247-51.
  75. Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM. Moving oncolytic viruses into the clinic: clinical-grade production purification and characterization of diverse oncolytic viruses. Mol Ther-Meth Clin D. 2016;3:E1-E12.
  76. Li N, Johnson DC, Weinhold N, Studd JB, Orlando G, Mirabella F, Mitchell JS, Meissner T, Kaiser M, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Nat Commun. 2016;7:13656 E1-E9.
  77. Deisenroth A, Sontgerath R, Schuster AJ, von Busch C, Huber G, Eckert K, Kulozik AE, Wiskemann J. Muscle strength and quality of life in patients with childhood cancer at early phase of primary treatment. Pediatr Hemat Oncol. 2016;33(6):393-407.
  78. Klassen O, Schmidt ME, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J. Muscle strength in breast cancer patients receiving different treatment regimes. Journal of cachexia, sarcopenia and muscle. 2016:E1-E12.
  79. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;28:142-8.
  80. Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology. 2016;17(7):883-95.
  81. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology. 2016;17(11):1590-8.
  82. Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Piperoglou C, Vely F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. 2016;6(1):E1-E13.
  83. Korkmaz-Icöz S, Al Said S, Radovits T, Li S, Brune M, Hegedus P, Atmanli A, Ruppert M, Brlecic P, Lehmann LH, Lahrmann B, Grabe N, Yoshikawa Y, Yasui H, Most P, Karck M, Szabo G. Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway. Cardiovascular diabetology. 2016;15:75E1-E16.
  84. Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-Cancer Analysis of Copy Number Changes in Programmed Death-Ligand 1 (PD-L1, CD274) - Associations with Gene Expression, Mutational Load, and Survival. Gene Chromosome Canc. 2016;55(8):626-39.
  85. Lotz J, Olesch J, Müller B, Polzin T, Galuschka P, Lotz JM, Heldmann S, Laue H, Gonzalez-Vallinas M, Warth A, Lahrmann B, Grabe N, Sedlaczek O, Breuhahn K, Modersitzki J. Patch-Based Nonlinear Image Registration for Gigapixel Whole Slide Images. Ieee T Bio-Med Eng. 2016;63(9):1812-9.
  86. Haense N, Atmaca A, Pauligk C, Steinmetz K, Marme F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420E1-E10.
  87. Ungar N, Wiskemann J, Sieverding M. Physical Activity Enjoyment and Self-Efficacy As Predictors of Cancer Patients' Physical Activity Level. Frontiers in psychology. 2016;7:898 E1-E10.
  88. Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia Lymphoma. 2016;57(12):2833-8.
  89. Wiskemann J, Hummler S, Diepold C, Keil M, Abel U, Steindorf K, Beckhove P, Ulrich CM, Steins M, Thomas M. POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment. BMC Cancer. 2016;16:499 E1-E9.
  90. Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK. Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Alcohol Clin Exp Res. 2016;40(10):2094-101.
  91. Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer letters. 2016;381(2):296-304.
  92. Vallet S, Bashari MH, Fan FJ, Malvestiti S, Schneeweiss A, Wuchter P, Jäger D, Podar K. Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway. PloS one. 2016;11(3):E1-E18.
  93. Wilms B, Schmid SM, Luley K, Wiskemann J, Lehnert H. Prevention and treatment of cachexia. Exercise and nutritional therapy. Internist. 2016;57(10):971-7.
  94. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jäger D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016;16(1):734E1-E9.
  95. Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128(4):594-602.
  96. Merz M, Moehler TM, Ritsch J, Bauerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J. Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur Radiol. 2016;26(5):1404-11.
  97. Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M. Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells. Cancer Res. 2016;76(8):2219-30.
  98. Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, Eichmüller SB, Jäger D, Waterboer T, Pawlita M, Brenner H. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;7(13):16420-32.
  99. Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengass J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer. 2016;16:290 E1-E10.
  100. Burkhardt D, Bartosova M, Schaefer B, Grabe N, Lahrmann B, Nasser H, Freise C, Schneider A, Lingnau A, Degenhardt P, Ranchin B, Sallay P, Cerkauskiene R, Malina M, Ariceta G, Schmitt CP, Querfeld U. Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. PloS one. 2016;11(11):E1-E14.
  101. De Souza Silveira R, Carlsohn A, Langen G, Mayer F, Scharhag-Rosenberger F. Reliability and day-to-day variability of peak fat oxidation during treadmill ergometry. Journal of the International Society of Sports Nutrition. 2016;13(4):E1-E7.
  102. Schmidt ME, Meynkohn A, Habermann N, Wiskemann J, Oelmann J, Hof H, Wessels S, Klassen O, Debus J, Potthoff K, Steindorf K, Ulrich CM. Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial. Int J Radiat Oncol. 2016;94(2):329-37.
  103. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497-503.
  104. Ungar N, Sieverding M, Weidner G, Ulrich CM, Wiskemann J. A self-regulation-based intervention to increase physical activity in cancer patients. Psychology, health & medicine. 2016;21(2):163-75.
  105. Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, Ulrich A. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 2016;16:949E1-E9.
  106. Mai EK, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731-41.
  107. Valous NA, Lahrmann B, Halama N, Bergmann F, Jäger D, Grabe N. Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors. Medical physics. 2016;43(6):2936-44.
  108. Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun. 2016;7:ncomms11845.
  109. Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC medicine. 2016;14(1):170 E1-E16.
  110. Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic oncology. 2016;34(10):433 e1-8.
  111. Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H, Group GCSW, the D. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016;62:1-8.
  112. Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-33.
  113. Moschetta M, Kawano Y, Podar K. Targeting the Bone Marrow Microenvironment. Cancer treatment and research. 2016;169:63-102.
  114. Schmidt M, Mock A, Jungk C, Sahm F, Ull AT, Warta R, Lamszus K, Gousias K, Ketter R, Roesch S, Rapp C, Schefzyk S, Urbschat S, Lahrmann B, Kessler AF, Löhr M, Senft C, Grabe N, Reuss D, Beckhove P, Westphal M, von Deimling A, Unterberg A, Simon M, Herold-Mende C. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget. 2016;7(12):14551-68.
  115. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, Miguel JS, van de Donk NWCJ, Einsele H, Blade J, Durie BGM, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62.
  116. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016;29(4):587-601.
  117. Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2016;16(6):329-34 E1-E7.
  118. Hassel JC, Lee SB, Meiss F, Meier F, Dimitrakopoulou-Strauss A, Jäger D, Enk AH. Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology. 2016;5(4):E1-E5.
  119. Weiss J, Gajek T, Köhler BC, Haefeli WE. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions. Pharmaceutics. 2016;8(1):E1-E13.
  120. Heining C, von Kalle C. What functions do oncological centers of excellence have in future research? Onkologe. 2016;22(3):152-7.

  1. Andersen JP, Bogsted M, Dybkaer K, Mellqvist UH, Morgan GJ, Goldschmidt H, Dimopoulos MA, Einsele H, San Miguel J, Palumbo A, Sonneveld P, Johnsen HE. Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. Plos One. 2015;10(1):e0116966.
  2. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jager D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology. 2015;4(4):e998538.
  3. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N, Transp ESBM. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transpl. 2015;50(2):209-215.
  4. Bashari MH, Fan F, Arn M, Vallet S, Opferman J, Cardone MH, Schneeweiss A, Jaeger D, Podar K. Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications. Breast. 2015;24:S37-S38.
  5. Baudendistel I, Winkler E, Kamradt M, Brophy S, Längst G, Eckrich F, Heinze O, Bergh B, Szecsenyi J, Ose D. The patients' active role in managing a personal electronic health record: a qualitative analysis. Support Care Cancer. 2015;23(9):2613-21.
  6. Baudendistel I, Winkler E, Kamradt M, Längst G, Eckrich F, Heinze O, Bergh B, Szecsenyi J, Ose D. Personal Electronic Health Records: Understanding User Requirements and Needs in Chronic Cancer Care. J Med Internet Res. 2015;17(5).
  7. Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH, Hecker M, Goerge T, Umansky L, Beckhove P, Utikal J, Gorzelanny C, Diaz-Valdes N, Umansky V, Schneider SW. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125(20):3153-3163.
  8. Bayo P, Jou A, Stenzinger A, Shao C, Gross M, Jensen A, Grabe N, Mende CH, Rados PV, Debus J, Weichert W, Plinkert PK, Lichter P, Freier K, Hess J. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Mol Oncol. 2015;9(8):1704-19.
  9. Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroentero. 2015;21(16):4911-4918.
  10. Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015;29(7):1555-1563.
  11. Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer. 2015;18(2):314-325.
  12. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schonland SO. Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. J Clin Oncol. 2015;33(12):1371-1377.
  13. Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garcia-Sanz R, Buda G, Gemignani F, Rios R, Vangsted AJ, Dumontet C, Martinez-Lopez J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SEH, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer. 2015;136(5):E351-E358.
  14. Carl D, Grüllich C, Hering S, Schabet M. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC research notes. 2015;8:316.
  15. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609-619.
  16. Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dancik V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MA, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell reports. 2015;10:755-770.
  17. Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, Hundemer M, Hillengass J, Alexi R, Goldschmidt H, Chen BA, Ho AD, Schmitt A. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 2015;55(2):275-283.
  18. Das T, Safferling K, Rausch S, Grabe N, Boehm H, Spatz JP. A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat Cell Biol. 2015;17(3):276-287.
  19. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BGM, Terpos E. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. J Clin Oncol. 2015;33(6):657-664.
  20. Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2015;100(10):1327-33.
  21. Dreikhausen L, Blank S, Sisic L, Heger U, Weichert W, Jäger D, Bruckner T, Giese N, Grenacher L, Falk C, Ott K, Schmidt T. Association of angiogenic factors with prognosis in esophageal cancer. Bmc Cancer. 2015;15:121.
  22. Fernandez-Ulibarri I, Hammer K, Arndt MAE, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer. 2015;136(9):2228-2240.
  23. Fichtner S, Hose D, Engelhardt M, Meissner T, Neuber B, Krasniqi F, Raab M, Schonland S, Ho AD, Goldschmidt H, Hundemer M. Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. Clin Cancer Res. 2015;21(7):1712-1721.
  24. Freudlsperger C, Horn D, Weissfuss S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, Hoffmann J, Freier K, Hess J. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer. 2015;136(12):2775-2785.
  25. Funk S, Mark R, Bayo P, Flechtenmacher C, Grabe N, Angel P, Plinkert PK, Hess J. High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer. 2015;136(9):2037-2046.
  26. Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB. Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice. Int J Cancer. 2015;136(11):2588-2597.
  27. Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RG, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta neuropathologica. 2015;130(3):419-34.
  28. George B, Horn D, Bayo P, Zaoui K, Flechtenmacher C, Grabe N, Plinkert P, Krizhanovsky V, Hess J. Regulation and function of Myb-binding protein 1A (MYBBP1A) in cellular senescence and pathogenesis of head and neck cancer. Cancer Lett. 2015;358(2):191-9.
  29. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015;21(12):2039-51.
  30. Gollhofer SM, Wiskemann J, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Hof H, Potthoff K, Steindorf K. Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. Bmc Cancer. 2015;15:186.
  31. Haag GM, Herrmann T, Jaeger D, Stremmel W, Schemmer P, Sauer P, Gotthardt DN. Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. BMC gastroenterology. 2015;15:171.
  32. Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Büchler MW, Springfeld C, Jäger D, Debus J, Combs SE. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol. 2015;13:1-7.
  33. Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, Schmitt M. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100(7):e285-8.
  34. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell research 2015;25(2):208-224.
  35. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25(3):399-400.
  36. Hecksteden A, Kraushaar J, Scharhag-Rosenberger F, Theisen D, Senn S, Meyer T. Individual response to exercise training - a statistical perspective. Journal of applied physiology 2015;118(12):1450-1459.
  37. Heining C, Richter D, Gröschel S, H. G, Fröling S. Integration der Genomsequenzierung in die klinische Hämato-Onkologie. klinikarzt. 2015;44(10):436-440.
  38. Hillengass J, Stoll J, Zechmann CM, Kunz C, Wagner B, Heiss C, Sumkauskaite M, Moehler TM, Schlemmer HP, Goldschmidt H, Delorme S. The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur Radiol. 2015;25(3):745-750.
  39. Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications. Urologe. 2015;54(6):800-803.
  40. Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. Bmc Cancer. 2015;15:392.
  41. Höfner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jäger D, Grüllich C. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World J Urol. 2015;33(6):833-839.
  42. Huber J, Ihrig A, Winkler E, Brechtel A, Friederich HC, Herzog W, Frank M, Grüllich C, Hallscheidt P, Zeier M, Pahernik S, Hohenfellner M. Interdisciplinary counseling service for renal malignancies: a patient-centered approach to raise guideline adherence. Urol Oncol. 2015;33(1):23 e1-7.
  43. Husedzinovic A, Ose D, Schickhardt C, Fröhling S, Winkler EC. Stakeholders' perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet. 2015;23(12):1607-14.
  44. Iacobelli S, de Wreede LC, Schonland S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kroger N, Gahrton G, CMWP E, Subcomm PCD. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transpl. 2015;50(4):505-510.
  45. Jäger D, Ma JH, Mardiak J, Ye DW, Korbenfeld E, Zemanova M, Ahn H, Guo J, Leonhartsberger N, Stauch K, Böckenhoff A, Yu J, Escudier B. Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study. Clin Genitourin Canc. 2015;13(2):156-164.
  46. Jiang HH, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352-2360.
  47. Kamradt M, Baudendistel I, Längst G, Kiel M, Eckrich F, Winkler E, Szecsenyi J, Ose D. Collaboration and communication in colorectal cancer care: a qualitative study of the challenges experienced by patients and health care professionals. Family practice. 2015;32(6):686-93.
  48. Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J, Bazhin AV. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Brit J Cancer. 2015;112(6):1027-1036.
  49. Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, Offringa R, Konig R, Bernhard H, Machlenkin A, Boutros M, Beckhove P. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. Embo Mol Med. 2015;7(4):450-463.
  50. Kiesgen S, Arndt MAE, Körber C, Arnold U, Weber T, Halama N, Keller A, Bötticher B, Schlegelmilch A, Liebers N, Cremer M, Herold-Mende C, Dyckhoff G, Federspil PA, Jensen AD, Jäger D, Kontermann RE, Mier W, Krauss J. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Lett. 2015;357(1):364-373.
  51. Kittas A, Barozet A, Sereshti J, Grabe N, Tsoka S. CytoASP: a Cytoscape app for qualitative consistency reasoning, prediction and repair in biological networks. BMC systems biology. 2015;9:34.
  52. Klupp F, Diers J, Kahlert C, Neumann L, Halama N, Franz C, Schmidt T, Lasitschka F, Warth A, Weitz J, Koch M, Schneider M, Ulrich A. Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma. Ann Surg Oncol. 2015;10.1245/s10434-015-4485-4.
  53. Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. Bmc Cancer. 2015;15(1):919.
  54. Kuehl R, Scharhag-Rosenberger F, Schommer K, Schmidt ME, Dreger P, Huber G, Bohus M, Ulrich CM, Wiskemann J. Exercise Intensity Classification in Cancer Patients Undergoing Allogeneic HCT. Med Sci Sport Exer. 2015;47(5):889-895.
  55. Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126(17):1996-2004.
  56. Laryionava K, Heussner P, Hiddemann W, Winkler EC. Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. Support Care Cancer. 2015;23(3):715-721.
  57. Lisenko K, Schonland S, Hegenbart U, Wallenwein K, Braun U, Mai EK, Hillengass J, Raab M, Jauch A, Ho AD, Goldschmidt H, Hundemer M. Potential therapeutic targets in plasma cell disorders: A flow cytometry study. Cytometry Part B, Clinical cytometry. 2015;10.1002/cyto.b.21351.
  58. Lohr J, Mock A, Beckhove P, Herold-Mende C. Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. Anticancer Res. 2015;35(5):2681-2690.
  59. Lorenzen S, Knorrenschild JR, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weissinger F, Schnoy E, Becker K, Stocker G, Ruschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51(5):569-576.
  60. Lotz J, Olesch J, Muller B, Polzin T, Galuschka P, Lotz J, Heldmann S, Breuhahn K, Gonzalez M, Lahrmann B, Grabe N, Laue H, Sedlaczek O, Warth A, Modersitzki J. Patch-Based Nonlinear Image Registration for Gigapixel Whole Slide Images. IEEE Transactions on Biomedical Engineering. 2015;10.1109/tbme.2015.2503122:1-1.
  61. Lupa DMW, Kalfalah F, Safferling K, Boukamp P, Poschmann G, Volpi E, Götz-Rösch C, Bernerd F, Haag L, Huelnenthal U, Fritsche E, Boege F, Grabe N, Tigges J, Stühler K, Krutmann J. Characterization of Skin Aging-Associated Secreted Proteins (SAASP) Produced by Dermal Fibroblasts Isolated from Intrinsically Aged Human Skin. J Invest Dermatol. 2015;135(8):1954-1968.
  62. Machiels JP, Specenier P, Krauss J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemoth Pharm. 2015;76(1):13-20.
  63. Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721-9.
  64. Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica. 2015;100(6):818-25.
  65. Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Transl Oncol. 2015;8(6):487-496.
  66. Meissner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC medical genomics. 2015;8:85.
  67. Merz M, Moehler TM, Ritsch J, Bauerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J. Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur Radiol. 2015;26(5):1404-11.
  68. Merz M, Ritsch J, Kunz C, Wagner B, Sauer S, Hose D, Moehler T, Delorme S, Goldschmidt H, Zechmann C, Hillengass J. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma. Clin Cancer Res. 2015;21(1):106-112.
  69. Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964-9.
  70. Merz M, Schweizer L, Kentar M, Schneider T, Goldschmidt H, Hillengass J. Extramedullary relapse after accidental head injury in a patient with multiple myeloma. Ann Hematol. 2015;94(2):351-353.
  71. Nienhueser H, Kunzmann R, Sisic L, Blank S, Strowitzk MJ, Bruckner T, Jäger D, Weichert W, Ulrich A, Büchler MW, Ott K, Schmidt T. Surgery of Gastric Cancer and Esophageal Cancer: Does Age Matter? J Surg Oncol. 2015;112(4):387-395.
  72. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9.
  73. Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Czlonkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH. Hepatobiliary malignancies in Wilson disease. Liver Int. 2015;35(5):1615-1622.
  74. Pfeil TA, Laryionava K, Reiter-Theil S, Hiddemann W, Winkler EC. What Keeps Oncologists From Addressing Palliative Care Early on With Incurable Cancer Patients? An Active Stance Seems Key. Oncologist. 2015;20(1):56-61.
  75. Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, Eichmüller SB, Jäger D, Enk A, Beckhove P. T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. Cancer Immunol Immun. 2015;64:1369-1381.
  76. Podar K. Toward optimizing pomalidomide therapy in MM patients. Blood. 2015;125(26):3968-9.
  77. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, Benner A, Büchler MW, Jäger D, Halama N, Khazaie K, Weitz J, Beckhove P. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis (vol 125, pg 739, 2015). J Clin Invest. 2015;125(3):1364-1364.
  78. Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, Benner A, Büchler MW, Jäger D, Halama N, Khazaie K, Weitz J, Beckhove P. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125(2):739-751.
  79. Reuter T, Warta R, Theile D, Meid AD, Rigalli JP, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herold-Mende C, Dyckhoff G, Haefeli WE, Weiss J. Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's archives of pharmacology. 2015;388(11):1141-50.
  80. Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. American journal of nuclear medicine and molecular imaging. 2015;5(5):469-78.
  81. Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med. 2015;40(6):e300-7.
  82. Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, Haberkorn U, Schlemmer HP, Delorme S, Dimitrakopoulou-Strauss A. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. American journal of nuclear medicine and molecular imaging. 2015;5(5):479-92.
  83. Safferling K, Sütterlin T, Grabe N. how wounds heal. systembiologiede. 2015(09):8-12.
  84. San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100(10):1334-9.
  85. Scharhag-Rosenberger F, Kuehl R, Klassen O, Schommer K, Schmidt ME, Ulrich CM, Wiskemann J, Steindorf K. Exercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations. J Cancer Surviv. 2015;10.1007/s11764-015-0437-z.
  86. Scharhag-Rosenberger F, Wiskemann J, Scharhag J. Cardiopulmonary exercise testing in cancer patients: should we really refrain from considering it for preparticipation screening? Oncologist. 2015;20(2):228.
  87. Schirrmacher V, Schlude C, Weitz J, Beckhove P. Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: Results from a phase I clinical study. Int J Oncol. 2015;46(1):71-77.
  88. Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer. 2015;137(2):471-480.
  89. Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Büchler MW, Ott K. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–1347.
  90. Schmidt T, Sisic L, Sterzing F, Haag GM, Kunzmann R, Grenacher L, Weichert W, Jäger D, Büchler MW, Ott K. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)]. Chirurg. 2015;86(10):955-62.
  91. Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015;4(4):e1001217.
  92. Schneider M, Korzeniewski N, Merkle K, Schüler J, Grüllich C, Hadaschik B, Hohenfellner M, Duensing S. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies. Urol Oncol. 2015;33(2):72 e1-7.
  93. Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, Safi S, Utikal J, Hoffmann H, Umansky V. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. Clin Exp Immunol. 2015;180(3):467-474.
  94. Schott S, Vallet S, Tower RJ, Noor S, Tiwari S, Schem C, Busch C. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. Invest New Drug. 2015;33(4):816-26.
  95. Schrader CH, Kolb M, Zaoui K, Flechtenmacher C, Grabe N, Weber KJ, Hielscher T, Plinkert PK, Hess J. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer. 2015;14:107.
  96. Schuol S, Schickhardt C, Wiemann S, Bartram CR, Tanner K, Eils R, Meder B, Richter D, Glimm H, von Kalle C, Winkler EC. So rare we need to hunt for them: reframing the ethical debate on incidental findings. Genome Med. 2015;7(1):83.
  97. Schwamb B, Pick R, Fernandez SBM, Völp K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J, Zörnig I, Hammerschmidt M, Nowak M, Penzel R, Zatloukal K, Joos S, Rieker RJ, Agaimy A, Söder S, Reid-Lombardo K, Kendrick ML, Bardsley MR, Hayashi Y, Asuzu DT, Syed SA, Ordog T, Zörnig M. FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer. 2015;137(6):1318-1329.
  98. Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D. miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression. Oncotarget. 2015;6(36):39165-83.
  99. Seidensaal K, Nollert A, Feige AH, Muller M, Fleming T, Gunkel N, Zaoui K, Grabe N, Weichert W, Weber KJ, Plinkert P, Simon C, Hess J. Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. Mol Cancer. 2015;14(1):204.
  100. Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Th. 2015;15(4):505-516
  101. Sklenarova H, Haun MW, Krümpelmann A, Friederich HC, Huber J, Thomas M, Winkler EC, Girgis A, Dinkel A, Herzog W, Hartmann M. Psychometric evaluation of the German Version of the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C-G) of cancer patients. Eur J Cancer Care. 2015;24(6):884-97.
  102. Sklenarova H, Krümpelmann A, Haun MW, Friederich HC, Huber J, Thomas M, Winkler EC, Herzog W, Hartmann M. When Do We Need to Care About the Caregiver? Supportive Care Needs, Anxiety, and Depression Among Informal Caregivers of Patients With Cancer and Cancer Survivors. Cancer. 2015;121(9):1513-1519.
  103. Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S905-14.
  104. Staffa L, Echterdiek F, Nelius N, Benner A, Werft W, Lahrmann B, Grabe N, Schneider M, Tariverdian M, Doeberitz MV, Blaker H, Kloor M. Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome - Molecular Alterations and Association with Clinical Parameters. Plos One. 2015;10(3).
  105. Steindorf K, Clauss D, Wiskemann J, Schmidt ME. Physical Activity and Gastrointestinal Cancers: Primary and Tertiary Preventive Effects and Possible Biological Mechanisms. Sports. 2015;3(3):145-148.
  106. Tauchert FK, Bankstahl US, Winkler EC, Hofheinz R, Marschner N, Quidde J, Hipp M, Hoeffkes HG, Weber M, Trojan J, Van Kampen M, Brueckl WM, Jaeger E, Al-Batran SE, Grp AQW. Changing symptom burden in cancer patients: Does physician-patient communication cover physical, psychological and social discomfort? A Survey among 2009 German patients. J Clin Oncol. 2015;33(15).
  107. Teichgräber V, Monasterio C, Chaitanya K, Boger R, Gordon K, Dieterle T, Jäger D, Bauer S. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci. 2015;60(2):264-272.
  108. Theile D, Allendorf D, Köhler BC, Jassowicz A, Weiss J. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines. J Pharm Pharmacol. 2015;67(11):1575-84.
  109. Ungar N, Sieverding M, Ulrich CM, Wiskemann J. What explains the intention to be physically active in cancer patients? Different determinants for active and insufficiently active patients. Journal of psychosocial oncology. 2015;33(1):15-33.
  110. Vallet S, Pahernik S, Höfner T, Tosev G, Hadaschik B, Duensing S, Sedlaczek O, Hohenfellner M, Jäger D, Grüllich C, NCT NCTD. Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clin Genitourin Canc. 2015;13(3):E145-E152.
  111. Vogel A, Kasper S, Weichert W, Bitzer M, Block A, Riess H, Schulze-Bergkamen H, Moehler MH, Merx KE, Endris V, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Kubicka S. Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol. 2015;33(15).
  112. Vogel A, Kullmann F, Kunzmann V, Riess H, Al-Batran SE, Oettle H, Plentz R, Siveke J, Springfeld C. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat. 2015;38(11):596-603.
  113. Waldera Lupa DM, Kalfalah F, Safferling K, Boukamp P, Poschmann G, Volpi E, Gotz-Rosch C, Bernerd F, Haag L, Huebenthal U, Fritsche E, Boege F, Grabe N, Tigges J, Stuhler K, Krutmann J. Characterization of Skin Aging-Associated Secreted Proteins (SAASP) Produced by Dermal Fibroblasts Isolated from Intrinsically Aged Human Skin. J Invest Dermatol. 2015;135(8):1954-68.
  114. Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M. T cell-based targeted immunotherapies for patients with multiple myeloma. Int J Cancer. 2015;136(8):1751-68.
  115. Weber T, Mavratzas A, Kiesgen S, Haase S, Botticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. Journal of immunology research. 2015;2015:561814.
  116. Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2015;101(3):e116-9.
  117. Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Duber C, Lang HK, Otto G, Worns MA, Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35(2):591-600.
  118. Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Worns MA, Galle PR, Schulze-Bergkamen H. Predictive Scores in Primary Biliary Cirrhosis A Retrospective Single Center Analysis of 204 Patients. J Clin Gastroenterol. 2015;49(5):438-447.
  119. Winkler E, Schildmann J. Decision making with patients with advanced cancer. A contribution from clinical ethics. Onkologe. 2015;21(7):630-636.
  120. Wiskemann J, Friedmann-Bette B. Potenzial körperlicher Aktivität in Prävention und Therapie chronisscher Erkrankungen. Aktuel Ernahrungsmed. 2015;40(389-408):20.
  121. Wiskemann J, Kleindienst N, Kuehl R, Dreger P, Schwerdtfeger R, Bohus M. Effects of physical exercise on survival after allogeneic stem cell transplantation. Int J Cancer. 2015;137(11):2749-2756.
  122. Wiskemann J, Kuehl R, Dreger P, Huber G, Kleindienst N, Ulrich CM, Bohus M. Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) - Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation. Bmc Cancer. 2015;15:619.
  123. Zhou XG, Li JL, Marx C, Tolstov Y, Rauch G, Herpel E, Macher-Goeppinger S, Roth W, Grullich C, Pahernik S, Hohenfellner M, Duensing S. Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma Prognostic and Translational Implications. Transl Oncol. 2015;8(6):480-486.
  124. Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jäger D. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer. 2015;136(1):138-151.

Lehr-/Handbücher

  1. Brücken bauen. Das Marsilius-Kolleg und seine fellows 2008-2014.
    Hrsg.: Just T, Rausch T, Schneidmueller B.
    Medizinethik als Grenzgang.
    Winkler EC.
    ISBN 978-3-8253-6368-0; 2014, S.248-250.
    Verlag: Universitätsverlag Winter, Heidelberg
  2. Computational biophysics of the skin.
    Hrsg.: Querleux B.
    Graphical multi-scale modeling of epidermal homeostasis with EPISIM.
    Suetterlin T, Grabe N.
    ISBN 978-981-4463-84-3; 2014, S. 421-460.
    Verlag: Pan Stanford Publishing, Singapore
  3. Fatigue bei Krebserkrankungen.
    Hrsg.: Heim R, Weis J.
    Sport- und Bewegungstherapie.
    Baumann FT, Wiskemann J.
    ISBN 978-3-7945-2946-9; 2014, S.154-165.
    Verlag: Schattauer Verlag, Stuttgart
  4. Therapeutic Antibodies, 2nd Edition.
    Hrsg.: Duebel S, Reichert JM.
    Antibody targeted drugs: from chemical immunoconjugates to recombinant fusion proteins.
    Krauss J, Mavratzas A, Arndt MAE, Kiesgen S.
    ISBN 978-3-527-32937-3; 2014 Sept.
    Verlag: Wiley VCH

Zeitschriften

  1. Efficacy of subcutaneous Bortezomib in the management of patients with multiple myeloma or relapsed mantle cell lymphoma
    Podar K.
    Clinical Medicine Insights: Therapeutics. 2014:6; 15-23. doi: 10.4137/CMT.S9308.
  2. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opfermann JT, Sattler M, Anderson KC, Jaeger D, Podar K.
    Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8.
  3. Generation of "LYmph Node Derived Antibody Libraries" (LYNDAL) for selecting fully human antiviral antibody fragments with therapeutic potential.
    Diebolder P, Keller A, Haase S, Schlegelmilch A, Kiefer JD, Karimi T, Weber T, Moldenhauer G, Kehm
    R, Eis-Hübinger AM, Jaeger D, Federspil PA, Herold-Mende C, Dyckhoff G, Kontermann RE, Arndt MA, Krauss J.
    MAbs. 2014 Jan-Feb;6(1):130-42.
  4. Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.
    Koehler BC, Jaeger D, Schulze-Bergkamen H.
    World J Gastroenterol. 2014 Feb 28;20(8):1923-34. doi: 10.3748/wjg.v20.i8.1923.
  5. Pan-Bcl-2 inhibitor Obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
    Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H.
    PLOS ONE 2014. (in press)
  6. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg
    Berger AK, Abel U, Komander C, Harig S, Jaeger D, Springfeld C.
    Pancreatology. 2014 May-Jun;14(3):211-5. doi: 10.1016/j.pan.2014.03.004. Epub 2014 Mar 18.
  7. Ethische Herausforderungen der Genomsequenzierung in der translationalen Forschung und Antworten aus dem EURAT-Projekt.
    Winkler EC, Schickhardt C.
    J Lab Med. 2014;38(4):211-220. doi: 10.1515/labmed-2014-0027, August 2014.
  8. Advance care planning in oncology – ethical and medical competences are needed.
    Schildmann J, Winkler EC.
    Oncol Res Treat. 2014;37(1-2). doi: 10.1159/000358160. 2014 Jan 24.
  9. Efficacy of exercise training in SCT patients-who benefits most?
    Wiskemann J, Kuehl R, Dreger P, Schwerdtfeger R, Huber G, Ulrich CM, Jaeger D, Bohus, M.
    Bone Marrow Transplant. 2014 Mar;49(3):443-8. doi: 10.1038/bmt.2013.194. Epub 2013 Dec 9.
  10. Multidisciplinary health care needs of psychologically distressed cancer patients in a Comprehensive Cancer Center.
    Schiel RO, Brechtel A, Hartmann M, Taubert A, Walther J, Wiskemann J, Roetzer I, Becker N, Jaeger D, Herzog W, Friederich HC.
    Dtsch Med Wochenschr. 2014 Mar;139(12):587-91. doi: 10.1055/s-0034-1369856. Epub 2014 Mar 11.
  11. The big mystery.
    Delorme S, Jaeger D.
    Radiologe. 2014 Feb;54(2):106. doi: 10.1007/s00117-013-2543-0.
  12. Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer - a single cancer-center experience.
    Haag GM, Apostolidis L, Jaeger D.
    Tumori. 2014 May-Jun;100(3):237-42. doi: 10.1700/1578.17188.
  13. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G1, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
    Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.
  14. Assessing patient-caregiver communication in cancer-a psychometric validation of the Cancer Communication Assessment Tool (CCAT-PF) in a German sample.
    Haun MW, Sklenarova H, Winkler EC, Huber J, Thomas M, Siminoff LA, Woll M, Brechtel A, Herzog W, Hartmann M.
    Support Care Cancer. 2014 Sep;22(9):2473-8. doi: 10.1007/s00520-014-2241-0. Epub 2014 Apr 11.
  15. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D, Gal Z, Warta R, Rigalli J, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G, Weiss J
    Cancer Biol Ther. 2014 April; 15:4, 436-442. doi: 10.4161/cbt.27632. Epub 2014 Jan 21.
  16. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zoernig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmueller SB, Jaeger D.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980. [Epub ahead of print].
  17. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.
    Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M.
    J Pathol. 2014 Jul 16. doi: 10.1002/path.4405. [Epub ahead of print]
  18. Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma.
    Campos B, Gal Z, Baader A, Schneider T, Sliwinski C, Gassel K, Bageritz J, Grabe N, von Deimling A, Beckhove P, Mogler C, Goidts V, Unterberg A, Eckstein V, Herold-Mende C.
    J Pathol. 2014 Sep;234(1):23-33. doi: 10.1002/path.4366.
  19. Stem cell Transplantation for Eradication of Minimal Pancreatic Cancer persisting after surgical Excision (STEMPACE Trial, ISRCTN47877138): study protocol for a phase II study.
    Schmitz-Winnethal FH, Schmidt T, Lehmann M, Beckhove P, Kieser M, Ho AD, Dreger, Buechler MW.
    BMC Cancer. 2014 Mar 10;14:168. doi: 10.1186/1471-2407-14-168.
  20. A vaccine targeting mutant IDH1 induces antitumour immunity.
    Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmueller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M.
    Nature. 2014 Aug 21;512(7514):327-327. doi: 10.1038/nature13387.
  21. Randomized controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life.
    Steindorf K, Schmidt ME, Klassen O, Ulrich C, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K.
    Ann Oncol. 2014 Aug 5; pii:mdu374.
  22. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
    Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, Hundemer M, Hillengass J, Alexi R, Goldschmidt H, Chen BA, Ho AD, Schmitt A.
    Transfusion. 2014 Aug 13. doi: 10.1111/trf.12813.
  23. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
    Breitkreutz I, Heiss C, Perne A, Beimler J, Jaeger D, Egerer G, Ho AD, Neben K, Zeier M, Goldschmidt H, Raab MS.
    Bone Marrow Transpl. 2014 Aug 4. doi: 10.1038/bmt.2014.165.
  24. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
    Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stępień A, Wątek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudziński M, Weinhold N, Reis RM, Canzian F.
    Int J Cancer. 2014 Jul 28. doi: 10.1002/ijc.29101.
  25. European Perspective on Multiple Myeloma Treatment Strategies in 2014.
    Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A.
    Oncologist. 2014 Aug;19(8):829-844.
  26. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma.
    Weinhold N, Foersti A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, Noethen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schoenland SO, Hemminki K.
    Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.208.
  27. Extramedullary relapse after accidental head injury in a patient with multiple myeloma.
    Merz M, Schweizer L, Kentar M, Schneider T, Goldschmidt H, Hillengass J.
    Ann Hematol. 2014 Jun 29. [Epub ahead of print]
  28. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
    Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.
    J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329.
  29. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.
    Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B.
    Oncotarget. 2014 May 15;5(9):2487-98.
  30. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.
    Wolf MB, Murray F, Kilk K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, Kauczor HU, Weber MA.
    Eur J Radiol. 2014 Jul;83(7):1222-30. doi: 10.1016/j.ejrad.2014.02.008.
  31. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
    Hundemer M, Engelhardt M, Bruckner T, Kraeker S, Schmitt A, Sauer S, Neben K, Witzens-Harig M, Goldschmidt H, Ho AD, Wuchter P.
    J Clin Apheresis. 2014 Apr 26. doi: 10.1002/jca.21323.
  32. Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology.
    Andrulis M, Baeuerle T, Goldschmidt H, Delorme S, Landgren O, Schirmacher P, Hillengass J.
    Eur J Radiol. 2014 Jun;83(6):970-4. doi: 10.1016/j.ejrad.2014.03.005.
  33. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
    Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F.
    Leuk Lymphoma. 2014 Jun 16:1-3. [Epub ahead of print] No abstract available.
  34. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK, Hillengass J, Listl K, Kilk K, Hielscher T, Landgren O, Delorme S, Goldschmidt H, Kauczor HU, Weber MA.
    Int J Cancer. 2014 Apr 7. doi: 10.1002/ijc.28877.
  35. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C, Goldschmidt H, Hose D, Pan L, Cheng C, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol I. 2014 Jul;41(7):1343-53. doi: 10.1007/s00259-014-2721-y.
  36. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
    Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS, Jauch A, Neben K, Hose D, Egerer G, Weber MA, Delorme S, Goldschmidt H, Hillengass J.
    Leukemia. 2014 Sep;28(9):1902-8. doi: 10.1038/leu.2014.75.
  37. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
    Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schoenland SO.
    Amyloid. 2014 Mar;21(1):9-17. doi: 10.3109/13506129.2013.854766.
  38. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.
    Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ, Yong K, Walker BA, Hoffmann P, Muehleisen TW, Langer C, Doerner E, Joeckel KH, Eisele L, Noethen MM, Hose D, Davies FE, Goldschmidt H, Morgan GJ, Hemminki K, Houlston RS.
    Blood. 2014 Apr 17;123(16):2513-7; quiz 2593. doi: 10.1182/blood-2013-10-532283.
  39. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
    Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, Goldschmidt H, Hillengass J.
    Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.
  40. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.
    Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.
    Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330.
  41. Inherited genetic susceptibility to multiple myeloma.
    Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, Hemminki K, Houlston RS.
    Leukemia. 2014 Mar;28(3):518-24. doi: 10.1038/leu.2013.344.
  42. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
    Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B.
    Brit J Haematol. 2014 Feb;164(4):613-6. doi: 10.1111/bjh.12660.
  43. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M, Adam P, Goldschmidt H, Fend F, Kanz L, Weisel K.
    Cl Lymph Myelom Leuk. 2014 Feb;14(1):e7-e11. doi: 10.1016/j.clml.2013.07.101.
  44. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
    Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Haenel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.
    Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585.
  45. IMWG consensus on risk stratification in multiple myeloma.
    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.
    Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247.
  46. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.
    Hillengass J, Weber MA, Kilk K, Listl K, Wagner-Gund B, Hillengass M, Hielscher T, Farid A, Neben K, Delorme S, Landgren O, Goldschmidt H.
    Leukemia. 2014 Jan;28(1):174-8. doi: 10.1038/leu.2013.244.
  47. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.
    Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz C, Benner A, Falk C, Weitz J, Koch M.
    Brit J Cancer. 2014 Jan 21;110(2):441-9. doi: 10.1038/bjc.2013.745.
  48. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.
    Chen H, Werner S, Tao S, Zoernig I, Brenner H.
    Cancer Lett. 2014 May 1;346(2):178-87. doi: 10.1016/j.canlet.2014.01.007.
  49. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
    Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jaeger D, von Kalle C, Ungerechts G.
    Mol Ther. 2014 Aug 26. doi: 10.1038/mt.2014.160.
  50. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
    Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jaeger D, von Kalle C, Ungerechts G.
    Cancer Gene Ther. 2014 Aug 22. doi: 10.1038/cgt.2014.40.
  51. Primary transcriptome map of the hyperthermophilic archaeon Thermococcus kodakarensis.
    Jaeger D, Foerstner KU, Sharma CM, Santangelo TJ, Reeve JN.
    BMC Genomics. 2014 Aug 16;15(1):684.
  52. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
    Hoefner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jaeger D, Gruellich C.
    World J Urol. 2014 Aug 12. doi: 10.1007/s00345-014-1375-5
  53. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zoernig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jaeger D.
    Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980.
  54. Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.
    Potthoff K, Habl G, Bruckner T, Suppan C, Hassel J, Jaeger D, Indorf M, Debus J.
    BMC Cancer. 2014 Apr 17;14:270. doi: 10.1186/1471-2407-14-270.
  55. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
    Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jaeger D, Buechler M, Bruckner T, Siewert J, Ott K.
    Gastric Cancer. 2014 Apr 11. doi: 10.1007/s10120-014-0367-x
  56. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
    Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jaeger D, Buechler MW, Weitz J, Koch M.
    BMC Cancer. 2014 Mar 11;14:174. doi: 10.1186/1471-2407-14-174.
  57. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
    Karakhanova S, Mosl B, Harig S, von Ahn K, Fritz J, Schmidt J, Jaeger D, Werner J, Bazhin AV.
    Int J Mol Sci. 2014 Mar 7;15(3):4104-25. doi: 10.3390/ijms15034104.
  58. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, Koenig J, Hoppe-Lotichius M, Hansen T, Pitton MB, Dueber C, Otto G, Schuchmann M, Galle PR, Woerns MA.
    J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.
  59. Predictive Scores in Primary Biliary Cirrhosis: A Retrospective Single Center Analysis of 204 Patients.
    Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Woerns MA, Galle PR, Schulze-Bergkamen H.
    J Clin Gastroenterol. 2014 Jul 10.  doi: 10.1097/MCG.0000000000000176
  60. Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.
    Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Tuereci O.
    Cancer Immunol Immun. 2014 Aug 28. doi: 10.1007/s00262-014-1596-x
  61. Classification of exercise intensities in hematological cancer patients during and after allo-HSCT.
    Kuehl R, Scharhag-Rosenberger F, Schommer K, Schmidt ME, Dreger P, Huber G, Bohus M, Ulrich CM, Wiskemann J.
    Med Sci Sport Exer. 2014 Sep 8. [Epub ahead of print]
  62. Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy.
    Klassen O, Schmidt ME, Scharhag-Rosenberger F, Sorkin M, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J.
    Acta Oncol. 2014 May 16:1-10.
  63. Irisin does not mediate resistance training-induced alterations in resting metabolic rate.
    Scharhag-Rosenberger F, Meyer T, Wegmann M, Ruppenthal S, Kaestner L, Morsch A, Hecksteden A.
    Med Sci Sports Exer. 2014 Sep;46(9):1736-43. doi: 10.1249/MSS.0000000000000286.
  64. Blood lactate concentrations are mildly affected by mobile gas exchange measurements.
    Scharhag-Rosenberger F, Wochatz M, Otto C, Cassel M, Mayer F, Scharhag J.
    Int J Sports Med. 2014 Jun;35(7):590-4. doi: 10.1055/s-0033-1354386.
  65. Can more than one incremental cycling test be performed within one day?
    Scharhag-Rosenberger F, Carlsohn A, Lundby C, Schueler S, Mayer F, Scharhag J.
    Eur J Sport Sci. 2014;14(5):459-67. doi: 10.1080/17461391.2013.853208.
  66. Limited benefit of Fatmax-test to derive training prescriptions.
    Schwindling S, Scharhag-Rosenberger F, Kindermann W, Meyer T.
    Int J Sports Med. 2014 Apr;35(4):280-5. doi: 10.1055/s-0033-1349106.
  67. Wissenschaftliche Studien zu körperlichem Training bei onkologischen Patienten: Empfehlungen zu den Erhebungsmethoden.
    Scharhag-Rosenberger F, Becker T, Streckmann F, Schmidt K, Berling A, Bernardi A, Engeroff T, Exner AK, Gutekunst K, Hofmeister D, Jensen W, Kaehnert H, Kneis S, Limbach M, Mau-Moelle A, Roecker K, Schmidt M, Schmidt T, Stoeckel T, Wehrle A, Wisemann J, Zimmer P, Zopf E, Steindorf K.
    Deutsche Zeitschrift für Sportmedizin. 2014 – in print.
  68. Nebenwirkungsorientierte Behandlungspfade für die bewegungstherapeutische Betreuung von onkologischen Patienten.
    Wiskemann J, Scharhag-Rosenberger F.
    B & G. 2014 30(4):146-150. doi: 10.1055/s-0034-1384418
  69. Physical performance and psychosocial status in lung cancer patients: results from a pilot study.
    Hummler S, Thomas M, Hoffmann B, Gaertner P, Zoz M, Huber G, Ulrich CM, Wiskemann J.
    Oncol Res Treat. 2014;37(1-2):36-41. doi: 10.1159/000358157.
  70. Exercise in patients with non-small cell lung cancer.
    Kuehr L, Wiskemann J, Abel U, Ulrich CM, Hummler S, Thomas M.
    Med Sci Sports Exer. 2014 Apr;46(4):656-63. doi: 10.1249/MSS.0000000000000158.
  71. Impact of resistance training in cancer survivors: a meta-analysis.
    Strasser B, Steindorf K, Wiskemann J, Ulrich N.
    Med Sci Sports Exer. 2013 Nov;45(11):2080-90. doi: 10.1249/MSS.0b013e31829a3b63.
  72. Exercise in breast cancer patients: impact on health.
    Schmidt M, Wiskemann J. Steindorf K.
    Breast Cancer Management. 2014 Vol. 3, No. 3, Pages 241-250 , doi: 10.2217/bmt.14.12
  73. What explains the intention to be physically active in cancer patients? – Different determinants for active and insufficiently active patients.
    Ungar N, Sieverding M, Ulrich CM, Wiskemann J.
    Psychosocial Oncology. 2014 (accepted)
  74. Factors influencing willingness for participation in an exercise intervention study in breast cancer patients during radiotherapy.
    Gollhofer SM, Wiskemann J, Schmidt M, Klassen O, Ulrich CM, Oelmann J, Hof H, Pottkopff K, Steindorf K.
    BMC Cancer. 2014 (submitted and under review)
  75. Standards der Sportmedizin: Krafttraining als Supportivtherapie bei onkologischen Patienten.
    Wiskemann J, Steindorf K.
    Deutsche Zeitschrift für Sportmedizin. 2014 65(1):22-24.
  76. Potential physiologic and molecular mechanisms linking endurance and resistance training with beneficial effects for cancer patients.
    Steindorf K, Schmidt ME, Wiskemann J, Ulrich CM.
    Deutsche Zeitschrift für Sportmedizin. 2014 (accepted)
  77. Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor Small Molecules in Oncology.
    Gruellich C.
    Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12.
  78. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review).
    Georgi B, Korzeniewski N, Hadaschik B, Gruellich C, Roth W, Sültmann H, Pahernik S, Hohenfellner M, Duensing S.
    Int J Oncol. 2014 Oct;45(4):1337-44. doi: 10.3892/ijo.2014.2567.
  79. Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactive in patients’ sera after full hematopoitic regeneration from allogeneic stem cell transplantation.
    Ziegler C, Finke J, Gruellich C.
    Transp Immunol. 2014 May;30(4):136-9. doi: 10.1016/j.trim.2014.03.005.
  80. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
    Roeder F, Lehner B, Schmitt T, Kasper B, Egerer G, Sedlaczek O, Gruellich C, Mechtersheimer G, Wuchter P, Hensley FW, Huber PE, Debus J, Bischof M.
    BMC Cancer. 2014 May 20;14:350. doi: 10.1186/1471-2407-14-350.
  81. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M, Schueler J, Hoefflin R, Korzeniewski N, Gruellich C, Roth W, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.
    Urol Oncol. 2014 Aug;32(6):877-84. doi: 10.1016/j.urolonc.2014.03.011.
  82. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal—Implications for targeted therapies.
    Schneider M, Korzeniewski N, Merkle K, Schueler J, Gruellich C, Hadaschik B, Hohenfellner M, Duensing S.
    Urol Oncol. 2014 Jul 1. pii: S1078-1439(14)00206-3. doi: 10.1016/j.urolonc.2014.06.001.
  83. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
    Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K.
    BMC Cancer. 2014 Feb 3;14:58. doi: 10.1186/1471-2407-14-58.
  84. Is preoperative chemotherapy followed by surgery the appropriate treatmet for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruchner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Bueckler M, Ott K.
    Ann Surg Oncol. 2014 May;21(5):1739-48. doi: 10.1245/s10434-013-3462-z.
  85. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Kraemer A, Klein B, Raab MS.
    Oncotarget. 2014 Sep 26. [Epub ahead of print]
  86. A gene expression signature for high-risk multiple myeloma.
    Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P.
    Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8.
    Erratum in: Leukemia. 2014 May;28(5):1178-80.
  87. T cell-based targeted immunotherapies for patients with multiple myeloma.
    Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M.
    Int J Cancer. 2014 Sep 6. doi: 10.1002/ijc.29190.
  88. Aprepitant, Granisetron and Dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose Melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
    Schmitt T, Goldschmidt H, Neben K, Freiberger A, Huesing J, Gronkowski M, Thalheimer M, Pelzl LH, Mikus G, Burhenne J, Ho AD, Egerer G.
    J Clin Oncol. 2014 Oct 20;32(30):3413-20. doi: 10.1200/JCO.2013.55.0095.
  89. State of the art treatment of progressive or refractory multiple myeloma.
    Schmidt-Wolf IG, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M.
    Dtsch Med Wochenschr. 2014 Oct;139(41):2091-5. doi: 10.1055/s-0034-1387268.
  90. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.
    Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H.
    PLoS One. 2014 Oct 16;9(10):e110591. doi: 10.1371/journal.pone.0110591. eCollection 2014.
  91. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I, Hammer K, Arndt MA, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM.
    Int J Cancer. 2014 Oct 10. doi: 10.1002/ijc.29258.
  92. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
    Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jaeger D, Buechler MW, Debus J.
    Ann Surg Oncol. 2014 Aug;21(8):2801-7. doi: 10.1245/s10434-014-3607-8.

Patentanmeldungen

  1. EP 14 18 399.2
    Construct for the delivery of a molecule into the cytoplasm of a cell
    Erfinder: Kiesgen S, Arndt MA, Krauss J.

Books/Manuals

    1. Praxisfelder angewandter Ethik: ethische Orientierung in Medizin, Politik, Technik und Wirtschaft.
      Hrsg.: Steger F, Hillerbrand R.
      Praktische Urteilskraft und institutionelle Ethik als Voraussetzungen für eine gute Entscheidungspraxis in der Klinik.
      Winkler EC.
      ISBN 978-3897857537; 2013, S. 67-80.
      Verlag: mentis, Münster
    2. Current & emerging therapeutics for multiple myeloma.
      Hrsg.: Raje N, Jagannath.
      Future directions.
      Podar K.
      e-ISBN: 978-1-78084-228-8; Sep 2013, S. 114-135. doi: 10.2217/ebo.13.249.
      Verlag: Future Medicine, London
    3. Advances in biology and therapy of multiple myeloma: volume 1: basic science.
      Hrsg.: Munshi NC, Anderson KC.
      Targeting multiple myeloma tumor angiogenesis: focus on VEGF.
      Podar K, Anderson KC.

      e-ISBN: 978-1-4614-4666-8; 2013, S. 283-299. doi: 10.1007/978-1-4614-4666-8_15.
      Verlag: Springer Science+Business Media, New York
    4. Psychoonkologie
      Hrsg.: Dorfmueller M, Dietzfelbinger H.
      Onkologische Ethik.
      Winkler EC.
      ISBN: 978-3-437-31602-9; 2013, 2. Auflage, S. 477-497. doi: -.
      Verlag: Elsevier Urban und Fischer

    Journals

    1. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Witzens-Harig M, Hose D, Juenger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P.
      Blood. 2013 May 30;121(22):4493-503. doi: 10.1182/blood-2012-05-429415. Epub 2013 Apr 19.
    2. Die Urologie im Konzept der „Comprehensive Cancer Center“.
      Hadaschik B, Pahernik S, Gruellich C, Sueltmann H, Jaeger D, von Kalle C, Duensing S, Hohenfellner M.
      Der Urologe.  2013/9:1283-1289. DOI: 10.1007/s00120-013-3313-3.
    3. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.
      Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Foersti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Noethen MM, Muehleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Doerner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.
      Nat Genet. 2013 Oct;45(10):1221-5. doi: 10.1038/ng.2733. Epub 2013 Aug 18.
    4. Onkologische Therapien – was sind patientenrelevante Endpunkte? Ehmann M, Haerter M, Rambach R, Winkler E.
      Onkologie. 2013; 36(suppl 6):5-8. doi: 10.1159/000353716.
    5. Multimodal oncological therapy concepts, chemotherapy and immunosuppressive drugs: effects on surgical morbidity and mortality. Berger AK, Jaeger D.
      Chirurg. 2013; 84(11) 930-6; doi: 10.1007/s00104-013-2512-1.
    6. Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
      Gronau M, Jaeger D, Enk AH, Hassel JC.
      Internal Med. 2013;52(1):151-2. Epub 2013 Jan 1.
    7. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort.
      Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jaeger D, Buechler MW, Debus J.
      Strahlenther Onkol. 2013 Sep;189(9):738-44. doi: 10.1007/s00066-013-0391-5. Epub 2013 Jul 31.
    8. Personalisierte Medizin und Informed consent: klinische und ethische Erwaegungen im Rahmen der Entwicklung einer best practice Leitlinie fuer die biobankbasierte Ganzgenomforschung in der Onkologie. Winkler EC, Ose D, Glimm H, Tanner K, von Kalle C.
      Ethik Med. (2013)25:195-203. doi:10.1007/s00481-013-0273-5.
    9. Stathmin regulates keratinocyte proliferation and migration during cutaneous regeneration.
      Schmitt S, Safferling K, Westphal K, Hrabowski M, Mueller U, Angel P, Wiechert L, Ehemann V, Mueller B, Holland-Cunz S, Stichel D, Harder N, Rohr K, Germann G, Matthaeus F, Schirmacher P, Grabe N, Breuhahn K.
      PLoS One. 2013 Sep 16;8(9):e75075. doi: 10.1371/journal.pone.0075075. eCollection 2013.
    10. Antitumor T cells responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
      Horn T, Grab J, Schusdziarra J, Schmid S, Maurer T, Nawroth R, Wolf P, Pritsch M, Gschwend JE, Kuebler HR, Beckhove P
      Int J Cancer. 2013 Nov;133(9):2145-56. doi: 10.1002/ijc.28233. Epub 2013 Jul 11.
    11. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas
      Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Hoefler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J.
      J Clin Invest. 2013 Jun 3;123(6):2488-501. doi: 10.1172/JCI67010. Epub 2013 May 1.
    12. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models
      Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, Grabe N, Veltkamp R.
      Brain Pathol. 2013 Jan;23(1):34-44. doi: 10.1111/j.1750-3639.2012.00614.x. Epub 2012 Aug 7.
    13. Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery.
      Koffler J, Holzinger D, Sanhueza GA, Flechtenmacher C, Zaoui K, Lahrmann B, Grabe N, Plinkert PK, Hess J.
      Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1493-500. doi: 10.1007/s00405-012-2201-6. Epub 2012 Oct 5.
    14. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
      Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, Beckhove P.
      Oncoimmunology. 2013 Jun 1;2(6):e24962. Epub 2013 May 15.
    15. B cell-regulated immune responses in tumor models and cancer patients.
      Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C.
      Oncoimmunology. 2013 Jul 1;2(7):e25443.
    16. Adoptive immunotherapy of metastatic breast cancer: present and future.
      Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C.
      Cancer Metast Rev. 2013 32(1-2):309-320.
    17. Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.
      Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C.
      Cancer Metast Rev. 2013; 32: 163-78.
    18. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.
      Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, Heil J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F.
      Cancer Immunol Immun. 2013 Jun;62(6):1053-60. doi: 10.1007/s00262-013-1414-x. Epub 2013 Apr 18.
    19. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
      Khan MW, Keshavarzian A, Gounaris E, Melson JE, Cheon EC, Blatner NR, Chen ZE, Tsai FN, Lee G, Ryu H, Barrett TA, Bentrem DJ, Beckhove P, Khazaie K.
      Clin Cancer Res. 2013 May 1;19(9):2342-54. doi: 10.1158/1078-0432.CCR-12-2623. Epub 2013 Mar 13.
    20. Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. Potthoff K, Schmidt ME, Wiskemann J, Hof H, Klassen O, Habermann N, Beckhove P, Debus J, Ulrich CM, Steindorf K.
      BMC Cancer. 2013 Mar 28;13:162. doi: 10.1186/1471-2407-13-162.
    21. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
      Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C.
      Cancer Immunol Immun. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.
    22. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
      Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V.
      J Immunol. 2013 Mar 1;190(5):2464-71. doi: 10.4049/jimmunol.1202781. Epub 2013 Jan 28.
    23. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
      Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von Knebel Doeberitz M, Kloor M.
      Cancer Immunol Immun. 2013 Jan;62(1):27-37. doi: 10.1007/s00262-012-1303-8. Epub 2012 Jun 23.
    24. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
      Combs SE, Habermehl D, Kieser M, Dreher C, Werner J, Haselmann R, Jaekel O, Jaeger D, Buechler MW, Debus J.
      BMC Cancer. 2013 Sep 14;13:419. doi: 10.1186/1471-2407-13-419.
    25. Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.
      Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D, Klein B.
      Haematologica. 2013 Sep;98(9):1442-9. doi: 10.3324/haematol.2012.066944. Epub 2013 Apr 12.
    26. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
      Avet-Loiseau, H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G.
      Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.
    27. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.
      Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.
      Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330. Epub 2014 Jan 21.
    28. Targeting the BRAF V600E mutation in multiple myeloma.
      Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.
      Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.
    29. Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?
      Lamers J, Hartmann M, Goldschmidt H, Brechtel A, Hillengass J, Herzog W.
      Psychooncology. 2013 Apr;22 (10):2313-2320. doi: 10.1002/pon.3284. [Epub ahead of print]
    30. Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases.
      Shah R, Stieltjes B, Andrulis M, Pfeiffer R, Sumkauskaite M, Delorme S, Schlemmer HP, Goldschmidt H, Landgren O, Hillengass J.
      Ann Hematol. 2013 Nov;92(11):1553-7. doi: 10.1007/s00277-013-1786-1. Epub 2013 May 17.
    31. Meeting report in the 4th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
      Hillengass J, Maximilian M, Goldschmidt H.
      J Cancer Res Clin. 2013 Nov;139(11):1807-11. doi: 10.1007/s00432-013-1468-3. Epub 2013 Jul 18.
    32. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
      Gahrton G, Iacobelli S, Bjoerkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schoenland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kroeger N.
      Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
    33. Wound healing revised: a novel reepithelialization mechanism revealed by in vitro and in silico models.
      Safferling K, Suetterlin T, Westphal K, Ernst C, Breuhan K, James M, Jaeger D, Halama N, Grabe N.
      J Cell Biol. 2013 Nov 25;203(4):691-709. doi: 10.1083/jcb.201212020.
    34. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
      Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.
      PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.
    35. Gene expression-based prediction of myeloma cells sensitivity to histone deacetylase inhibitors.
      Moreaux J, Reme T, Leonard W, Veyrune JL. Requirand G, Goldschmidt H, Hose D, Klein B.
      Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.
    36. Hepatitis B virus infection is associated with deletion of chronmosome 8p in multiple myeloma.
      Becker N, Byl A, Friedrich S, Jauch A, Schnitzler P, Egerer G, Ho AD, Goldschmidt H, Neben K
      Eur J Haematol. 2013 Apr;90(4):279-85. doi: 10.1111/ejh.12018. Epub 2012 Nov 22.
    37. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.
      Lancet Oncol. 2013 Oct;14(11):1055-66. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
    38. Bortezomib-based versus Nonbortezomib-basedinduction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
      Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
      J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
    39. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
      Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC.
      Lancet Oncol. 2013 Oct;14(11):1129-40. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19.
    40. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.
      Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfel.d C.
      Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.
    41. Advanced-stage pancreatic cancer: therapy options.
      Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buechler MW.
      Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30.
    42. A reliable risk score for stage IV esophagogasstric cancer.
      Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Blaeker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jaeger D, Buechler M, Siewert JR, Ott K.
      Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.00.83505. Epub 2013 Jan 31.
    43. Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.
      Schmitt S, Hielscher T, Baldus C, Neben K, Egerer G, Hillengaß J, Raab M, Hose D, Ho AD, Bergner R, Goldschmidt H, Moehler TM.
      Int J Hematol. 2013 Jun;97(6):765-72. doi: 10.1007/s12185-013-1320-1. Epub 2013 Apr 25.
    44. Posterior reversible leukoencephalopathy syndrome associated with pazopanib.
      Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K.
      Case Rep Oncol. 2013 Apr 6;6(1):204-8. doi: 10.1159/000350742. Print 2013 Jan.
    45. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
      Aigner J, Marmé F, Smetanay K, Schuetz F, Jaeger D, Schneeweiss A.
      Anticancer Res. 2013 Aug;33(8):3407-13.
    46. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
      Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jaeger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.
      Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.
    47. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue.
      Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, Herpel E, Kloor M, Ulrich A, Schneider M, Ulrich CM, Robins H.
      Cancer Immunol Immun. 2013 Sep;62(9):1453-61. doi: 10.1007/s00262-013-1446-2. Epub 2013 Jun 16.
    48. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.
      Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, Hengel H, Jaeger D, Schneweis KE, Eis-Huebinger AM, Roggendorf M, Krauss J.
      P Natl Acad Sci USA. 2013 Apr 23;110(17):6760-5. doi: 10.1073/pnas.1220019110. Epub 2013 Apr 8.
    49. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.
      Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, Bergmann F, Debus J, Jaeger D, Buechler M, Werner J.
      Ann Surg Oncol. 2013 Mar;20(3):964-72. doi: 10.1245/s10434-012-2762-z. Epub 2012 Dec 12.
    50. Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
      Berger AK, Weber TF, Jaeger D, Springfeld C.
      Onkologie. 2013;36(12):763-5. doi: 10.1159/000356811. Epub 2013 Nov 20.
    51. Improvement of surgical results for pancreatic cancer.
      Hartwig W, Werner J, Jaeger D, Debus J, Buechler MW.
      Lancet Oncol. 2013 Oct;14(11):e476-85. doi: 10.1016/S1470-2045(13)70172-4.
    52. Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG).
      Sisic L, Blank S, Weichert W, Jaeger D, Springfeld C, Hochreiter M, Buechler M, Ott K.
      Langenbeck Arch Surg. 2013 Oct;398(7):973-81. doi: 10.1007/s00423-013-1101-6. Epub 2013 Jul 26.
    53. New treatment strategies for multiple myeloma.
      Goldschmidt H, Nitschmann S.
      Internist. 2013 Jul;54(7):892-6. doi: 10.1007/s00108-013-3299-3.
    54. Therapeutic strategies in multiple myeloma: the future role of bendamustine
      Goldschmidt H, Kropff M, Muegge LO, Poenisch W.
      Onkologie. 2013;36 Suppl 1:19-26. doi: 10.1159/000346107. Epub 2013 Jan 28.
    55. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
      Vallet S, Podar K.
      Expert Opin Biol Th. 2013 Jun;13 Suppl 1:S35-53. doi: 10.1517/14712598.2013.807337. Epub 2013 Jun 17. Review.
    56. Multistage histopathological image segmentation of Iba1-stained murine microglias in a focal ischemia model: methodological workflow and expert validation.
      Valous NA, Lahrmann B, Zhou W, Veltkamp R, Grabe N.
      J Neurosci Meth. 213 (2013) 250-262. doi: 10.1016/j.jneumeth.2012.12.017.
    57. Thalidomide maintenance therapy maturates the T-cell compartment and compromises antigen specific antitumor immunity in patients with multiple myeloma.
      Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M.
      Exp Hematol. 2013 Mar;41(3):231-40. doi: 10.1016/j.exphem.2012.10.018. Epub 2012 Nov 8.
    58. Autologous retransplantation for patients with recurrent multiple myeloma: A single-center experience with 200 patients.
      Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H, Neben K.
      Cancer. 2013 Jul 1;119(13):2438-46. doi: 10.1002/cncr.28104. Epub 2013 Apr 10.
    59. Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.
      Munder M, Engelhardt M, Knies D, Medenhoff S, Wabnitz G, Luckner-Minden C, Feldmeyer N, Voss RH, Kropf P, Mueller I, Conradi R, Samstag Y, Theobald M, Ho AD, Goldschmidt H, Hundemer M.
      PLoS One. 2013 May 23;8(5):e63521
    60. The glycome of normal and malignant plasma cells.
      Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.
      PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.
    61. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
      Weinhold N, Johnson DC, Chubb D, Chen B, Foersti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Noethen MM, Muehleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K.
      Nat Genet. 2013 May;45(5):522-5. doi: 10.1038/ng.2583. Epub 2013 Mar 17.
    62. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.
      Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE.
      PLoS One. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. eCollection 2013.
    63. Progression in smoldering myeloma Is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
      Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
      J Clin Oncol. 2013 Dec 1;31(34):4325-32. doi: 10.1200/JCO.2012.48.4923. Epub 2013 Oct 21.
    64. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.
      Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jaeger D, Buechler M, Ott K.
      Langenbeck Arch Surg. 2013 Feb;398(2):211-20. doi: 10.1007/s00423-012-1034-5. Epub 2012 Dec 7.
    65. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
      Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jaeger D, Buechler M, Siewert JR, Lordick F.
      Langenbeck Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27.
    66. Rationing cancer care: a survey among the members of the german society of hematology and oncology.
      Krause SW, Schildmann J, Lotze Ch, Winkler EC.
      J Natl Compr Canc Netw. 2013 Jun 1;11(6):658-65.
    67. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
      Woerns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstaetter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.
      Digest Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.
    68. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9.
      Fritsch K, Finke J, Gruellich C.
      Ann Hematol. 2013 Dec;92(12):1603-9. doi: 10.1007/s00277-013-1846-6. Epub 2013 Jul 28.
    69. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
      Marmé F, Aigner J, Lorenzo Bermejo J, Sinn P, Sohn C, Jaeger D, Schneeweiss A.
      Int J Cancer. 2013 Aug 15;133(4):1006-15. doi: 10.1002/ijc.28094. Epub 2013 Mar 16.
    70. Semantic Focusing Allows Fully Automated Single-Layer Slide Scanning of Cervical Cytology Slides.
      Lahrmann B, Valous NA, Eisenmann U, Wentzensen N, Grabe N.
      PloS  One. 8(4): e61441. doi: 10.1371/journal.pone.0061441.
    71. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.
      Halama N, Spille A, Lerchl T, Brand K, Herpel E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C, Weitz J, Grabe N, Jaeger D, Zoernig I.
      OncoImmunology. 2:4, e24116; April 2013. doi: 10.4161/onci.24116.
    72. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
      Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
      Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.
    73. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
      Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jaeger D, Schulze-Bergkamen H.
      PLoS One. 2013 Oct 3;8(10):e76446. doi: 10.1371/journal.pone.0076446. eCollection 2013.
    74. CD24 polymorphisms in breast cancer: impact on prognosis and risk.
      Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jaeger D, Flesch-Janys D, Chang-Claude J, Marmé F.
      Breast Cancer Res Tr. 2013 Feb;137(3):927-37. doi: 10.1007/s10549-012-2325-9. Epub 2013 Jan 13.
    75. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway.
      Holzinger D, Flechtenmacher C, Henfling N, Kaden I, Grabe N, Lahrmann B, Schmitt M, Hess J, Pawlita M, Bosch FX.
      Int J Cancer. 2013 Sep 15;133(6):1389-99. doi: 10.1002/ijc.28142. Epub 2013 Mar 29.
    76. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
      Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM.
      Oncology. 2013;84(1):6-13. doi: 10.1159/000342425. Epub 2012 Oct 13.
    77. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
      Elsing C, Herrmann C, Hannig CV, Stremmel W, Jaeger D, Herrmann T.
      Oncology. 2013;85(5):262-8. doi: 10.1159/000355690. Epub 2013 Oct 29.
    78. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
      Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schaekel K, Garbi N, Jaeger D, Weitz J, Schmitz-Winnenthal H, Haemmerling GJ, Beckhove P.
      Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.
    79. Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance.
      Zoernig I, Ziegelmeier C, Lahrmann B, Grabe N, Jaeger D, Halama N.
      Oncol Rep. 2013 May;29(5):1697-700. doi: 10.3892/or.2013.2324. Epub 2013 Mar 5.
    80. Bridging the scales: semantic integration of quantitative SBML in graphical multi-cellular models and simulations with EPISIM and COPASI.
      Suetterlin T, Kolb C, Dickhaus H, Jaeger D, Grabe N.
      Bioinformatics. 2013 Jan 15;29(2):223-9. doi: 10.1093/bioinformatics/bts659. Epub 2012 Nov 18.
    81. Urology in the concept of comprehensive cancer centers
      Hadaschik B, Pahernik S, Gruellich C, Sueltmann H, Jaeger D, von Kalle C, Duensing S, Hohenfellner M.
      Urologe A. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3.
    82. B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort.
      Zschaebitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, Miller JW, Song X, Maneval DR, Beresford SA, Lane D, Shikany JM, Ulrich CM.
      Am J Clin Nutr. 2013 Feb;97(2):332-43. doi: 10.3945/ajcn.112.034736. Epub 2012 Dec 19.
    83. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
      Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P.
      Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101.
    84. Sorafenib in patients with refractory or recurrent multiple myeloma.
      Yordanova A, Hose D, Neben K, Witzens-Harig M, Gütgemann I, Raab MS, Moehler T, Goldschmidt H, Schmidt-Wolf IG.
      Hematol Oncol. 2013 Dec;31(4):197-200. doi: 10.1002/hon.2043.

    Lehr-/Handbücher

    1. Prävention und Versorgung.
      Hrsg.: Kirch W, Hoffmann T, Pfaff H.
      Patientenorientierte Versorgungsforschung – Grundlagen, Methoden und Perspektiven.
      Ose D, Freund T, Winkler EC, Ludt S.
      ISBN 978-3-13-169451-5; 2012, S. 464-477.
      Verlag: Thieme, Stuttgart

    2. Multiple myeloma – a new era of treatment strategies.
      Hrsg.: Podar K, Anderson KC.
      Guideline to multiple myeloma treatment strategies.
      Podar K, Kaufmann JL, Laubach J, Lonial S, Richardson PG, Anderson KC.
      ISBN: 978-1-60805-609-5.
      e-ISBN: 978-1-60805-297-4; 2012, S. 73-87.
      doi: 10.2174/97816080529741120101.
      Verlag: bentham science publishers

    3. Multiple myeloma – a new era of treatment strategies.
      Hrsg.: Podar K, Anderson KC.
      New therapeutic strategies in multiple myeloma.
      Podar K, Hideshima T, Chauhan D, Anderson KC.
      ISBN: 978-1-60805-609-5.
      e-ISBN: 978-1-60805-297-4; 2012, S. 161-183. doi: 10.2174/97816080529741120101.
      Verlag: bentham science publishers

    4. Multiple myeloma – a new era of treatment strategies.
      Hrsg.: Podar K, Anderson KC.
      Pathogenesis and treatment of bone disease in multiple myeloma.
      Vallet S, Raje N.
      ISBN: 978-1-60805-609-5.
      e-ISBN: 978-1-60805-297-4; 2012, S. 161-183. doi: 10.2174/97816080529741120101.
      Verlag: bentham science publishers

    5. Rationelle Diagnostik und Therapie in der Inneren Medizin.
      Multiples Myelom.
      Goldschmidt H.
      ISBN: 978-3-437-22827-8; 2012, Bd. 11: S. 1-6. doi: -
      06.

    6. Onkologie 2012/2013. Interdisziplinäre Empfehlungen zur Therapie.
      Hrsg.: Preiß J, Dornoff W, Hagmann FG, Schmieder A.
      Multiples Myelom (MM, Plasmozytom).
      Goldschmidt H.
      ISBN: 978-3-86371-042-2; 2012, S. 57-61. doi: -.
      Verlag: W. Zuckschwerdt Verlag, München

    7. Praxisbuch Ethik in der Intensivmedizin.
      Hrsg.: Salomon F.
      Die institutionelle moralische Verantwortung der Klinik.
      Winkler EC.
      ISBN: 978-3-941-46874-0; 2012, S. 123-129. doi: -.
      Verlag: Med. Wissenschaftliche Verlagsgesellschaft, Berlin


    Journals

    1. Deriving new treatment strategies.
      Podar K.
      Int J Hematol. 2012;1(1)1-6.

    2. Targeting the tumor microenvironment: Focus on angiogenesis.
      Fan F, Schimming A, Jaeger D, Podar K.
      J Oncol. 2012;2012:281261. doi: 10.1155/2012/281261. Epub 2011 Aug 24.

    3. MM-associated anemia: more than “crowding out” HSPCs.
      Podar K.
      Blood. 2012; Sep 27;120(13):2539-40.

    4. Novel  targets and derived small molecule inhibitors in multiple myeloma.
      Podar K.
      Curr Cancer Drug Tar. 2012 Sep;12(7):797-813.

    5. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.
      Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Kraemer A.
      Cancer Res. 2012 Oct 15;72(20):5374-85. doi: 10.1158/0008-5472.CAN 12-2026. Epub 2012 Aug 31.

    6. Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors
      Moreaux J, Rème T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.
      Mol Cancer Ther. 2012 Dec;11(12):2685-92. doi: 10.1158/1535-7163.MCT-12-0721. Epub 2012 Oct 18.

    7. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
      Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.
      PLoS One. 2012;7(7):e42161. doi: 10.1371/journal.pone.0042161. Epub 2012 Jul 31.

    8. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
      Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.
      J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

    9. A gene expression signature for high-risk multiple myeloma.
      Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P.
      Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8. Erratum in: Leukemia. 2014 May;28(5):1178-80.

    10. Clinical and prognostic role of annexin A2 in multiple myeloma.
      Seckinger A, Meißner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Rème T, Roesen-Wolff A, Jauch A, Schmettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D.
      Blood. 2012 Aug 2;120(5):1087-94. doi: 10.1182/blood-2012-03-415588. Epub 2012 Jun 15.

    11. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and sdurvival in multiple myeloma.
      Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R, Hose D, Delorme S, Goldschmidt H, Neben K.
      Haematologica. 2012 Nov;97(11):1757-60. doi: 10.3324/haematol.2012.065359. Epub 2012 Jun 11.

    12. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
      Dimopoulos MA, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky R.
      Cancer Treat Rev. 2012 Dec;38(8):1012-9. doi: 10.1016/j.ctrv.2012.02.009. Epub 2012 May 18. Review.

    13. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMEnSE consortium.
      Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi S, Canzian F.
      Br J Haematol. 2012 May;157(3):331-8. Epub 2012 Feb 13.

    14. European perspective on multiple myeloma treatment strategies: update following recent congresses.
      Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Hess U, Mellqvist UH, Moreau P, San-Miguel J, Sondergeld P, Sonneveld P, Udvardy M, Palumbo A.
      Oncologist. 2012;17(5):592-606. doi: 10.1634/theoncologist.2011-0391. Epub 2012 May 9.

    15. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
      Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S.
      Leukemia Lymphoma. 2012 Sep;53(9):1820-3. doi: 10.3109/10428194.2012.661175. Epub 2012 Mar 1.

    16. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma research (IMMEnSE) consortium.
      Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM.
      Leukemia. 2012 Jun;26(6):1419-22. doi: 10.1038/leu.2011.352. Epub 2011 Dec 20.

    17. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
      Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Duehrsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.
      Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8.

    18. Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma a technique to evaluate angiogenic response to therapy?
      Zechmann CM, Traine L, Meißner T, Wagner-Gund B, Giesel FL, Goldschmidt H, Delorme S, Hillengass J.
      Acad Radiol. 2012 Jan;19(1):100-8. doi: 10.1016/j.acra.2011.09.007.

    19. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.
      Broderick P, Chubb D, Johnson DC, Weinhold N, Foersti A, Lloyd A, Olver B, Ma YP, Dobbins SE, Walker BA, Davies FE, Gregory WA, Child JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Muehleisen TW, Noethen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS.
      Nat Genet. 2011 Nov 27;44(1):58-61. doi: 10.1038/ng.993.

    20. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.
      Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.
      Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.

    21. MAGIC (MyelomA Genetics International Consortium).
      Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim CS, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R.
      Leuk Lymphoma. 2012 May;53(5):796-800. doi: 10.3109/10428194.2011.639881. Epub 2012 Jan 3.

    22. Meeting report of the third Heidelberg myeloma workshop: current status and developments in diagnosis and therapy of multiple myeloma.
      Hillengass J, Neben K, Goldschmidt H.
      J Cancer Res Clin. 2012 Jan;138(1):173-8. doi: 10.1007/s00432-011-1071-4. Epub 2011 Sep 30.

    23. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
      Vallet S, Witzens-Harig M, Jaeger D, Podar K.
      Expert Opin Pharmaco. 2012 Mar;13(4):473-94. doi: 10.1517/14656566.2012.656091. Epub 2012 Feb 13.

    24. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
      Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jaeger D, Capussotti  L, Kunz R, Buechler MW.
      J Clin Oncol. 2012 Nov 20;30(33):4077-83. doi: 10.1200/JCO.2011.38.2960. Epub 2012 Sep 24.

    25. Eine ethische Orientierungshilfe: Therapieverzicht gegen den Patientenwillen?
      Winkler EC, Marckmann G.
      ÄBW. (4) 2012:140-144.

    26. Aenderung des Therapieziels am Lebensende: Effekte einer Klinik-Leitlinie.
      Jox RJ, Winkler EC, Borasio GD.
      Deut Med Wochenschr. 2012; 137(16):829-833.

    27. Evaluating a patient’s request for life-prolonging treatment: an ethical framework.
      Winkler EC, Hiddemann W, Marckmann G.
      J Med Ethics. 2012 Nov;38(11):647-51. doi: 10.1136/medethics-2011-100333. Epub 2012 Jun 12.

    28. Interdisziplinaere Therapiekonzepte bei kolorektalen Lebermetastasen.
      Schulze-Bergkamen H, Jaeger D.
      Viszeralmedizin. 2012 (28):43-49.

    29. Liver specific deletion of CYLDexon 7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
      Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hoevelmeyer N, Hahn M, Schuchmann M, Jaeger D, Waisman A, Woerns MA, Schulze-Bergkamen H.
      J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21.

    30. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
      Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, Kalle CV, Ungerechts G.
      Cancer Gene Ther. 2012 Mar;19(3):181-91. doi: 10.1038/cgt.2011.75. Epub 2011 Nov 11.

    31. Emerging trends in oncology testing: enhancing the medical value of diagnostics.
      Rohr UP, Walk E, Teichgraeber V, Liesenfeld O, Batria R, Lee JA.
      Clpmag.com. 2012 42(9):8-13

    32. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.
      Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.
      Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.

    33. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinat envelope protein booster.
      Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cataneo R.
      J Virol. 2012 Nov;86(21):11558-66. doi: 10.1128/JVI.01776-12. Epub 2012 Aug 15.

    34. Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study.
      Kasperk C, Haas A, Hillengass J, Weiss C, Neben K, Goldschmidt H, Sommer U, Nawroth P, Meeder PJ, Wiedenhoefer B, Schmidmaier G, Tanner M, Neuhof D, Noeldge G, Grafe IA.
      J Surg Oncol. 2012 Jun 1;105(7):679-86. doi: 10.1002/jso.22101. Epub 2011 Sep 29.

    35. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
      Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International myeloma working group study.
      Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.

    36. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
      Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jaeger D, Olson DL, Sattler M, Chauhan D, Anderson KC.
      Brit J Haematol. 2011 Nov;155(4):438-48. doi: 10.1111/j.1365-2141.2011.08864.x. Epub 2011 Sep 19.

    37. 5-Fluorouracil and interferon-α  immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
      Khallouf H, Maerten A, Serba A, Teichgraeber V, Buechler MW, Jaeger D, Schmidt J.
      J Immunother. 2012 Apr;35(3):245-53. doi: 10.1097/CJI.0b013e31824b3a76.

    38. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
      Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jaeger D.
      BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108.

    39. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.
      Combs SE, Kieser M, Habermehl D, Weitz J, Jaeger D, Fossati P, Orrechia R, Engenhart-Cabillic R, Poetter R, Dosanjh M, Jaekel O, Buechler MW, Debus J.
      BMC Cancer. 2012 Apr 3;12:137. doi: 10.1186/1471-2407-12-137.

    40. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).
      Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jaeger D, Luntz SP, Englert S, Rossion I, Koch M, Buechler MW, Kieser M, Weitz J; SYNCHRONOUS trial group.
      BMC Cancer. 2012 Apr 5;12:142. doi: 10.1186/1471-2407-12-142.

    41. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
      Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hoevelmeyer N, Hahn M, Schuchmann M, Jaeger D, Waisman A, Woerns MA, Schulze-Bergkamen H.
      J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21.

    42. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer.
      Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, Debus J, Jaeger D, Buechler MW, Werner J.
      Surgery. 2012 Sep;152(3 Suppl 1):S33-42. doi: 10.1016/j.surg.2012.05.029. Epub 2012 Jul 6.

    43. Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy.
      Kahlert C, Gaitzsch E, Steinert G, Mogler C, Jansen L, Benner A, Chang-Claude J, Klupp F, Schmidt T, Grabe N, Lahrmann B, Halama N, Weitz J.
      Ann Surg Oncol. 2012 Dec;19(13):4193-201. doi: 10.1245/s10434-012-2518-9. Epub 2012 Aug 10.

    44. The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead.
      Halama N, Zoernig I, Grabe N, Jaeger D.
      Oncoimmunology. 2012 Jan 1;1(1):62-66.

    45. Sequential metastases of colorectal cancer. Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments.
      Keim S, Zoernig I, Spille A, Lahrmann B, Brand K, Herpel E, Grabe N, Jaeger D, Halama N.
      Oncoimmunology. 2012 Aug 1:5,593-599.

    46. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
      Loehr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Foelsch UR, Jaeger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP; CT4001 Study Group.
      Ann Oncol. 2012 May;23(5):1214-22. doi: 10.1093/annonc/mdr379. Epub 2011 Sep 6.

    47. Multistage histopathological image segmentation of Iba1-stained murine microglias in a focal ischemia model: Methodological workflow and expert validation.
      Valous NA, Lahrmann B, Zhou W, Veltkamp R, Grabe N.
      J Neurosci Meth. 213 (2013) 250-262. doi: 10.1016/j.jneumeth.2012.12.017.

    48. Bridging the scales: semantic integration of quantitative SBML in graphical multi-cellular models and simulations with EPISIM and COPASI
      Suetterlin T, Kolb C, Dickhaus H, Jaeger D, Grabe N.
      Bioinformatics.2013 Jan 15;29(2):223-9. doi: 10.1093/bioinformatics/bts659.Epub 2012 Nov 18.

    49. Revisiting the training of logic models of protein signaling networks with ASP.
      Videla S, Guziolowski C, Eduati F, Thiele S, Grabe N, Saez-Rodriguez J, Siegel A.
      Computational Methods in Systems Biology. Series: Lecture Notes in Computer Science. 2012 Vol 7605:342-361.

    50. Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery.
      Koffler J, Holzinger D, Sanhueza GA, Flechtenmacher C, Zaoui K, Lahrmann B, Grabe N, Plinkert PK, Hess J.
      Eur Arch Oto-Rhino-L. 2012 05. October 2012; doi: 10.1007/s00405-012-2201-6.

    51. Potential canonical Wnt pathway activation in high-grade astrocytomas
      Schuele R, Dictus C, Campos B, Wan F, Felsberg J, Ahmadi R, Centner F, Grabe N, Reifenberger G, Bermejo J, Unterberg A, Herold-Mende C.
      The Scientific World Journal. 2012:697313. doi: 10.1100/2012/697313. Epub 2012 Aug 2.

    52. In silico accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types.
      Gupta SK, Srivastava M, Akhoon BA, Gupta SK, Grabe N.
      Infect Genet Evol.  2012 Oct;12(7):1513-8. doi: 10.1016/j.meegid.2012.02.022. Epub 2012 May 24.

    53. Automatic generation of causal networks linking growth factor stimuli to functional cell state changes.
      Guziolowski C, Kittas A, Dittmann F, Grabe N.
      FEBS J.  2012 Sep;279(18):3462-74. doi: 10.1111/j.1742-4658.2012.08616.x. Epub 2012 May 22.

    54. Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
      Jensen AD, Krauss  J, Potthoff  K, Simon C, Nikoghosyan AV, Lossner K, Debus J, Munter MW.
      Radiat Oncol. 2012 Apr 2;7:57. doi: 10.1186/1748-717X-7-57.

    55. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
      Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.
      Invest New Drug. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.

    56. Fulminant liver failure in Wilson's disease with histologic features of postinfantile giant cell hepatitis; cytomegalovirus as the trigger for both?
      Welte S, Gagesch M, Weber A, Longerich T, Millonig G.
      Eur J Gastroenterol Hepatol. 2012 Mar;24(3):328-31. doi: 10.1097/MEG.0b013e3283506843.